Two-Drug cocktail targets Hard-to-Treat hodgkin lymphoma

NCT ID NCT03681561

Recruiting now Disease control Sponsor: Veronika Bachanova Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two drugs—nivolumab and ruxolitinib—together in people whose Hodgkin lymphoma has returned or not responded to treatment. The goal is to find the safest dose of ruxolitinib when combined with a fixed dose of nivolumab, and to see if the combination can control the cancer for at least 3 months. About 54 adults will take part in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (Opdivo) and ruxolitinib (Jakafi)
What this could lead to: If successful, this combination could offer a new treatment option for people with Hodgkin lymphoma that has not responded to standard therapies.
What could go wrong: This is an early-phase trial with only 54 participants, so results may not apply to everyone. The combination may cause significant side effects or fail to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA

Contacts and locations

Locations

Indiana Melvin and Bren Simon Comprehensive Cancer Center
WITHDRAWN

Indianapolis, Indiana, 46202, United States
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
University of Illinois Cancer Center
COMPLETED

Chicago, Illinois, 60612, United States
University of Iowa Hospitals and Clinics
ACTIVE_NOT_RECRUITING

Iowa City, Iowa, 52242, United States
University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States
University of Wisconsin
RECRUITING

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.